Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biomarker Based Neoadjuvant Strategies for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
NCT06601309Phase 2Recruiting
- Sponsor
- Fujian Medical University Union Hospital
- Start
- Jul 2024
- Primary completion
- Mar 2027
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of serplulimab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Fujian Medical University Union Hospital. Started Jul 2024; status: recruiting.
02
Drugs
serplulimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT06601309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06601309.